UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company’s key growth drivers are already reflected in consensus expectations.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
- Novartis initiated with an Underweight at Morgan Stanley
- Novartis agrees to acquire Anthos for up to $3.1B
- Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos